Key Insights on Gross Profit: AstraZeneca PLC vs Pfizer Inc.

AstraZeneca's steady rise vs Pfizer's volatile profits.

__timestamp	AstraZeneca PLC	Pfizer Inc.
Wednesday, January 1, 2014	20253000000	40028000000
Thursday, January 1, 2015	20062000000	39203000000
Friday, January 1, 2016	18876000000	40495000000
Sunday, January 1, 2017	18147000000	41306000000
Monday, January 1, 2018	17154000000	42399000000
Tuesday, January 1, 2019	19463000000	41531000000
Wednesday, January 1, 2020	21318000000	33216000000
Friday, January 1, 2021	24980000000	50467000000
Saturday, January 1, 2022	31960000000	65986000000
Sunday, January 1, 2023	37771000000	28809000000

Unveiling the hidden dimensions of data

AstraZeneca vs Pfizer: A Decade of Gross Profit Trends

In the ever-evolving pharmaceutical industry, AstraZeneca PLC and Pfizer Inc. have been pivotal players. From 2014 to 2023, these giants have showcased contrasting trajectories in gross profit. AstraZeneca's gross profit surged by approximately 86%, peaking in 2023, while Pfizer experienced a more volatile journey, with a notable dip in 2023, marking a 28% decrease from its 2022 high. This divergence highlights AstraZeneca's steady growth strategy, contrasting with Pfizer's fluctuating performance, possibly influenced by its dynamic product portfolio and market conditions. The data underscores the importance of strategic planning and market adaptability in the pharmaceutical sector. As investors and industry watchers analyze these trends, the insights offer a glimpse into the financial health and strategic directions of these two industry titans.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025